# LXEO — Lexeo Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** LXEO  
**Sources:** 15  
**Published:** 2026-10-30  
**Canonical:** https://app.k3vl4r.com/research/deep-research-lxeo-lexeo-therapeutics-inc-catalysts-narrative-risks-10125

---

## Lexeo Therapeutics (NASDAQ: LXEO) — Research Summary

As of 2026-10-30, Lexeo is a clinical-stage genetic-medicine company using adeno-associated virus (AAV) delivery to target cardiovascular and CNS genetic diseases with high unmet need. Its two lead programs are **LX2006** for Friedreich's ataxia (FA) cardiomyopathy and **LX2020** for PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM), alongside a candidate for APOE4-related Alzheimer's disease (LX1001) [[2]](https://www.marketbeat.com/instant-alerts/event-lexeo-therapeutics-maps-gene-therapy-milestones-eyes-key-2027-readout-2026-10-25/)[[3]](https://finance.yahoo.com/healthcare/articles/lexeo-therapeutics-eyes-nsvt-data-070203299.html)[[12]](https://www.marketbeat.com/stocks/NASDAQ/LXEO/)[[15]](https://stockanalysis.com/stocks/lxeo/). Market capitalization is roughly **$251 million**, with a share price near **$3.06** as of 2026-10-29 [[12]](https://www.marketbeat.com/stocks/NASDAQ/LXEO/)[[15]](https://stockanalysis.com/stocks/lxeo/).

## Key Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-lxeo-lexeo-therapeutics-inc-catalysts-narrative-risks-10125 (free to sign up)._